Clinical trials: Cardiac Perfusion
Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
- Trial name
- Re-PERFUSE (NCT06611423)
- Testing
- AZD3427, Dopamine, Radiolabelled ligand
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cardiovascular Disease
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension
The primary objective of the double-blind segment is to compare effects of alagebrium vs placebo on change from baseline in endothelial function, as assessed by flow-mediated vasodilation (FMD).
- Trial name
- NCT00302250
- Testing
- ALT-711 (alagebrium chloride)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Synvista Therapeutics, Inc
Coronary Artery Disease (CAD)
An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD.
- Trial name
- NCT03354273
- Testing
- PET MPI, SPECT MPI, Pharmacological stress agents
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 730 people
- Sponsor
- GE Healthcare
Myocardial Ischemia, Coronary Disease
Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
This study is being conducted to provide access to and collect test data for an established nuclear medicine diagnostic imaging test called Positron Emission Tomography (PET), using a specific radioactive drug called Ammonia N-13…
- Conditions
- Myocardial Ischemia, Coronary Disease, Coronary Artery Disease, Heart Diseases
- Trial name
- NCT04343209
- Testing
- Myocardial Perfusion Imaging Study, AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]
- Where
- 5 sites in United States
- Volunteers
- 170 people
- Sponsor
- Ionetix Corporation
Coronary Artery Disease
Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging
This study was designed to evaluate the ability of AI-700-enhanced rest-stress echocardiography to detect coronary artery disease (CAD) in patients with suspected ischemic heart disease who are indicated for single-photon…
- Trial name
- NCT00156793
- Testing
- AI-700 contrast-enhanced echocardiography
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Acusphere
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595244
- Testing
- PB127 for injectable suspension
- Where
- 15 sites in United States
- Volunteers
- 456 people
- Sponsor
- Point Biomedical
Stable Angina, Non-ST-elevation Acute Coronary Syndrome
Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI)…
- Conditions
- Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
- Trial name
- NCT06436092
- Where
- 32 sites in Japan
- Volunteers
- 280 people
- Sponsor
- TCROSS Co., Ltd.
Coronary Artery Perforation
Investigation of the Ringer Perfusion Balloon Catheter
The objective of this study is to demonstrate reasonable assurance that the Ringer catheter can be safely used to manage hemorrhage due to coronary vessel perforations while facilitating distal perfusion under the conditions of…
- Trial name
- NCT04849169
- Testing
- Experimental
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vascular Solutions LLC
Coronary Artery Disease
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.
- Trial name
- NCT00594698
- Testing
- PB127 for injectable suspension
- Where
- 34 sites in United States
- Volunteers
- 150 people
- Sponsor
- Point Biomedical
Fontan, Right Heart Failure
Cholate Clearance in Fontan and Heart Failure
The goal of this study is to use the HepQuant dual cholate clearance assay, which has been shown to measure liver function in people with known chronic liver conditions, to assess severity of Fontan-associated liver disease…
- Trial name
- NCT07009132
- Testing
- Dual cholate clearance assay, MRI
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- HepQuant, LLC
Coronary Artery Disease (CAD)
A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)
This long-term study will follow patients with known or suspected of having coronary artery disease (CAD) and have participated in present and future BMS747158 clinical studies.
- Trial name
- NCT01085162
- Testing
- BMS747158
- Where
- United States
- Sponsor
- Lantheus Medical Imaging
Coronary Artery Disease
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007
This trial is to compare PB127 echocardiography to other heart imaging studies.
- Trial name
- NCT00595673
- Testing
- PB127 for injectable suspension
- Where
- 19 sites in United States
- Volunteers
- 428 people
- Sponsor
- Point Biomedical
Coronary Artery Disease
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
This a Phase 3, prospective, open-label, multicenter study of [15-O]-H2O injection for PET imaging of subjects with suspected CAD.
- Trial name
- NCT05134012
- Testing
- [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 215 people
- Sponsor
- MedTrace Pharma A/S
Coronary Artery Disease
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-imaging (SPECT-MPI)to detect defects in the supply of blood to the heart muscle…
- Trial name
- ASPECT2 (NCT01313572)
- Testing
- Apadenoson SPECT-MPI, Adenosine SPECT-MPI
- Where
- 86 sites in United States, Argentina and 3 more
- Volunteers
- 197 people
- Sponsor
- Forest Laboratories
Coronary Artery Disease
A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"
[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial…
- Trial name
- NCT02720354
- Testing
- [11C]-DMDPA
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Synektik S.A.
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the variability of several pharmacodynamic measures of kidney function, cardiovascular function, cerebral perfusion, and haemodynamics.
- Trial name
- NCT01551446
- Testing
- Bardoxolone Methyl
- Sponsor
- Biogen
Coronary Artery Disease
Direct Comparison of 2D Cardiac PET With 3D Cardiac PET
Lowering the per-infusion dose of Rb-82 offers advantages of lessening radiation exposure and extending useable generator life. Prior studies have not shown equivalence of 3D vs 2D Rb-82 PET.
- Trial name
- NCT01993303
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Cardiovascular Imaging Technologies
Coronary Artery Disease
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208312
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 787 people
- Sponsor
- Gilead Sciences
Coronary Artery Disease
ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
- Trial name
- NCT00208299
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 1,231 people
- Sponsor
- Gilead Sciences